ZYTIGA® (abiraterone acetate) in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Estimate based on sales and use data from April 2011 to December 2016.
Significant results and an established safety profile.
View Clinical Study Data
Identifying the cost support options available to your patients.
Discover Cost Support Options
Understanding the role of prednisone in treatment.
Understand the Role of Prednisone
Learn About The Janssen Heritage
Content area 1.2